# Aureka Biotechnologies

Antibody drug discovery driven by generative AI and digital biology



Canonical: https://uniquebase.ai/companies/aureka-biotechnologies
Stable identifier: UB-C5576
Snapshot captured: 2026-10-20T18:05:01.520Z
English updated: 2026-10-20T18:23:30.014Z

## Funding

Listed 3 records.
Latest: $100M (Series B), 2026-08-11.
Total raised (as reported): nearly $200M, as of 2026-08-11.

- 2026-08-11 · $100M · Series B · Granite Asia, Qiming Venture Capital, 弘晖基金, 纽尔利资本, 经纬创投 · https://elsewhere.news/zh/5ycapital/1bai-5y-news
  > On 2026/8/11, Elsewhere reported that Chinese biological AI company Xunming Shengke raised USD 100 million in Series B funding, bringing total funding close to USD 200 million. The round was completed in stages, with proceeds supporting biological foundation model R&D and training at scale. (translated source brief)
- 2026-04-28 · $35M · Series A+ · Hongshan China, Qiming Venture Capital, 五源资本, 博远资本, 纽尔利资本, 经纬创投
  > On 2026-04-28, according to Xiniu Data, Aureka Biotechnologies completed Series A+ financing, raising USD 35 million. Investors were lead investor Hongshan China, Jingwei Venture Capital, Boyuan Capital, Wuyuan Capital and others. The company is a developer of antibody drugs using generative AI. (translated source brief)
- 2025-11-10 · Tens of millions of US dollars · Series A · Agentic Ventures, Qiming Venture Capital, 五源资本, 纽尔利资本

## Valuation

Listed 3 records.

- 2026-08-11 · amount unavailable · Series B · Granite Asia, Qiming Venture Capital, 弘晖基金, 纽尔利资本, 经纬创投 · https://elsewhere.news/zh/5ycapital/1bai-5y-news
  > On 2026/8/11, Elsewhere reported that Chinese biological AI company Xunming Shengke raised USD 100 million in Series B funding, bringing total funding close to USD 200 million. The round was completed in stages, with proceeds supporting biological foundation model R&D and training at scale. (translated source brief)
- 2026-04-28 · amount unavailable · Series A+ · Hongshan China, Qiming Venture Capital, 五源资本, 博远资本, 纽尔利资本, 经纬创投
  > On 2026-04-28, according to Xiniu Data, Aureka Biotechnologies completed Series A+ financing, raising USD 35 million. Investors were lead investor Hongshan China, Jingwei Venture Capital, Boyuan Capital, Wuyuan Capital and others. The company is a developer of antibody drugs using generative AI. (translated source brief)
- 2025-11-10 · amount unavailable · Series A · Agentic Ventures, Qiming Venture Capital, 五源资本, 纽尔利资本

## Revenue

Listed 1 record.

- 2026-08-11 · 过去两年实现千万美元级商业收入 · Series B · Granite Asia, Qiming Venture Capital, 弘晖基金, 纽尔利资本, 经纬创投 · https://elsewhere.news/zh/5ycapital/1bai-5y-news
  > On 2026/8/11, Elsewhere reported that Chinese biological AI company Xunming Shengke raised USD 100 million in Series B funding, bringing total funding close to USD 200 million. The round was completed in stages, with proceeds supporting biological foundation model R&D and training at scale. (translated source brief)

## Team

No published team profiles are linked yet.

## Products

No published products profiles are linked yet.

## Investors

- [Agentic Ventures](/institutions/agentic-ventures)
- [Granite Asia](/institutions/granite-asia)
- [Hongshan China](/institutions/hongshan-china)
- [Qiming Venture Capital](/institutions/qiming-venture-capital)
- [五源资本](/institutions/wuyuan-capital)
- [博远资本](/institutions/UB-I2854)
- [弘晖基金](/institutions/honghui-fund)
- [纽尔利资本](/institutions/niuerli-capital)
- [经纬创投](/institutions/jingwei-venture-capital)

## Sources

- No source links are available for this profile.